CDX
A-431
Tumor indication
Skin
Tumor subtype
Epidermoid (Squamous cell) Carcinoma
Description
A-431 (Epidermoid Carcinoma CDX Model)
The A-431 epidermoid carcinoma line was derived from a vulvar carcinoma. It is well known for very high expression of epidermal growth factor receptor (EGFR). This makes A-431 a gold standard model for EGFR-targeted drug development. Its reproducible biology supports both mechanistic and translational studies.
Key Features:
- Originates from vulvar epidermoid carcinoma.
- Overexpresses EGFR at high levels.
- Strong epithelial morphology.
- Benchmark model for EGFR research.
Applications:
A-431 is used to test EGFR inhibitors and antibodies in preclinical research. It is applied in studies of EGFR signaling and downstream pathways. Researchers often use it to evaluate therapeutic efficacy in epithelial cancers. Its consistent overexpression makes it valuable for benchmarking targeted therapies.
Details
- Tumor indication
- Skin
- Tumor subtype
- Epidermoid (Squamous cell) Carcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.